Please assess the completion status of the following clinical trial:

Trial Title: Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Age greater than or equal to 18 years.~HIV-1 infection confirmed by ELISA and Western Blot before screening.~Category A or B HIV-1 infection.~Antiretroviral treatment:~* started at least 12 months prior to screening visit;~* stable and continuous for at least 12 weeks prior to screening visit;~* modified no more than once for virologic failure.~IL-2 naive~CD-4(+) T-lymphocyte count greater than or equal to 500 cells/mm(3) in the twelve weeks prior to screening (historical) and at screening.~Nadir CD4(+) T-lymphocyte count greater than or equal to 200 cells/mm(3) prior to screening visit (that is, no measurement whose values may be less than 200/mm(3) since diagnosis of the HIV infection.~Plasma HIV RNA less than 50 copies/ml in the 12 weeks preceding screening (historical, less than limit of detection if different method and/or cut off used) and at screening.~For women of child-bearing age: use of effective contraception (hormonal such as birth control pill or injections, intrauterine device, surgical sterilization and/or mechanical barrier methods such as diaphragm or condoms); for all participants agreement to fully comply with prevention of transmission recommendations during periods of viremia if sexually active (latex condoms with or without additional barrier methods).~Desire to interrupt antiretroviral therapy.~Ability to sign informed consent (no later than W-2).~EXCLUSION CRITERIA:~Previous treatment with IL-2.~Combined treatment with interferon, other interleukins, anti-HIV vaccines, systemic (not topical or inhaled) corticosteroids and hydroxyurea within the previous 12 weeks.~Diagnosis of AIDS.~Acute infection in the 14 days preceding inclusion.~Pregnant, lactating woman desiring conception or not using contraception.~Hemoglobin less than 10 g/dl; neutrophils less than 1,000/mm(3); platelets less than 50,000/mm(3); creatinine greater than 1.5 times the upper limit of normal (N); bilirubin greater than 3N; AST or ALT greater than 3 N.~Progressive disease of malignant, psychiatric, cardiac, pulmonary, thyroid, renal or neurological (peripheral or central) origin or severe disorders of hemostasis.~Severe uncontrolled hypertension.~Previous or progressive pathology contraindicating the administration of IL-2.~History of extensive psoriasis, Crohn's disease or auto-immune disease involving severe complications.~HTLV-1 infection (ELISA positive).~Hepatitis B virus co-infection treated with lamivudine or tenofovir or adefovir.~Since atazanavir use can be associated with higher bilirubin levels (mostly indirect) in the absence of clinical consequences, subjects on atazanavir with bilirubin up to 4.5 times N may be allowed to participate if the levels have been stable and after approval by the PI or the PI designated covering physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interleukin 2 group (Type: ACTIVE_COMPARATOR): HAART (standard of care) and three cycles of IL-2
- Control group (Type: ACTIVE_COMPARATOR): HAART alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete